GSK Exploring Tykerb Potential In Patients Not Previously Treated With Herceptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Subset of breast cancer patients given lapatinib plus paclitaxel first line shows significant advantage in progression-free survival, duration of response.